Seven nodes which strongly linked gene modules (bottleneck hubs) were identified as possible therapeutic targets which include IL6, AKT1, TP53, TNF, JUN, VEGFA, and PPARG. Elevated levels of IL6 have been previously documented in patients with NAFLD [139] and AD [140]. The gene discussed is TP53; the disease is metabolic dysfunction-associated steatotic liver disease.